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Estrogen-regulated genes (in breast cancer) <p>Estrogen-regulated gene expression profiles of <it>in vivo </it>breast tumor cell lines and <it>in vitro </it>xenografts and breast  tumors are remarkably similar.</p>
Abstract
Background: Estrogen plays a central role in breast cancer pathogenesis. Although many studies
have characterized the estrogen regulation of genes using in vitro cell culture models by global
mRNA expression profiling, it is not clear whether these genes are similarly regulated in vivo or
how they might be coordinately expressed in primary human tumors.
Results: We generated DNA microarray-based gene expression profiles from three estrogen
receptor α (ERα)-positive breast cancer cell lines stimulated by 17β-estradiol (E2) in vitro over a
time course, as well as from MCF-7 cells grown as xenografts in ovariectomized athymic nude mice
with E2 supplementation and after its withdrawal. When the patterns of genes regulated by E2 in
vitro were compared to those obtained from xenografts, we found a remarkable overlap (over 40%)
of genes regulated by E2 in both contexts. These patterns were compared to those obtained from
published clinical data sets. We show that, as a group, E2-regulated genes from our preclinical
models were co-expressed with ERα in a panel of ERα+ breast tumor mRNA profiles, when
corrections were made for patient age, as well as with progesterone receptor. Furthermore, the
E2-regulated genes were significantly enriched for transcriptional targets of the myc oncogene and
were found to be coordinately expressed with Myc in human tumors.
Conclusion: Our results provide significant validation of a widely used in vitro model of estrogen
signaling as being pathologically relevant to breast cancers in vivo.
Background
Estrogenic hormones are key regulators of growth, differenti-
ation, and function in a wide array of target tissues, including
the male and female reproductive tracts, mammary gland,
and skeletal and cardiovascular systems. Many of the effects
of estrogens are mediated via their nuclear receptors,
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estrogen receptor (ER)α and ERβ. The estrogen receptors
mediate a number of effects within the cell, mainly by altering
the transcription of genes via direct interaction with their
promoters or through binding to other proteins, which in turn
interact with and regulate gene promoters [1]. It has been
well-established that estrogen plays a significant role in
breast cancer development and progression [2]. Increased
lifetime exposure to estrogen is a factor in breast cancer risk
[3], and drugs that block the effects of estrogen can inhibit the
growth of hormone dependent breast cancers and prevent
breast cancer [4].
Although much is known about the role of estrogen signaling
in breast cancer proliferation, it is still not known which genes
are critical for breast pathogenesis. One goal that would help
our understanding of the role of estrogen in breast cancer is
to characterize the ERα-mediated transcriptional regulatory
network. Several studies have been published using DNA
microarrays to identify ERα-regulated genes by monitoring
the global mRNA expression patterns in breast cancer cells
stimulated by estrogen [5-11]. Beyond cataloging the individ-
ual genes in the ERα gene network, much could be discovered
by considering the gene expression patterns as a whole and
how patterns of estrogen regulation may relate to patterns
obtained from mRNA profiling studies of other experimental
systems and of human tumors. In particular, we examine here
how estrogen-induced mRNA expression patterns observed
in in vitro cell line models correspond to expression patterns
in breast tumors in vivo, especially in ERα+ breast tumors.
We also show how the transcriptional program of estrogen
response  in vitro is observed in large part in an in vivo
xenograft experimental model. Furthermore, we show an
enrichment of estrogen signaling target genes for genes tran-
scriptionally activated by the myc oncogene.
Results
The global gene expression profile of estrogen 
response in multiple breast cell lines shows temporal 
complexity
We studied the gene expression patterns induced in three
separate ERα-positive, estrogen dependent breast cancer cell
lines (MCF-7, T47D and BT-474) grown in steroid-depleted
medium or in the presence of 17β-estradiol (E2). After treat-
ment for intervals varying from 1 to 24 hours, total RNA was
extracted from the cells (MCF-7, 10 different RNA samples in
total; T47D, 14 samples in total; BT-474, 10 samples in total)
and analyzed using Affymetrix Genechip Arrays representing
22,283 mRNA transcripts (12,768 unique named genes). We
sought genes with expression patterns common to all three
cell lines that were correlated with the proliferative behavior
of the cells in response to E2 treatment. Expression values
within each cell line were first transformed to standard devi-
ations from the mean, in order to compensate for cell line-
specific, but not E2-specific, differences. As observed else-
where [7], we anticipated that E2-induced mRNA expression
changes would be temporally complex, occurring at various
time points, and so as an initial selection for differentially
expressed genes, we compared the 4, 8, 12, and 24 hour time
points across all three cell lines with the 0 time point of E2
treatment. Genes that showed significant up- or down-regu-
lation (p < 0.01) for at least one time point were selected for
further analysis; 1,989 transcripts (representing 1,592 unique
named genes) showed up-regulation and 1,516 transcripts
(1,277 genes) were down-regulated (the complete list is pro-
vided in Additional data file 1).
As we tested about 22,000 genes for significance of expres-
sion, many genes may give a nominally significant p value by
chance alone. Permutation of the sample labels indicated that
on the order of 25% of the 3,501 transcripts (4 transcripts of
the 1,989 that showed up-regulation at one time point also
showed down-regulation at another time point) selected by
our above criteria might be spurious. Alternatively, we might
have used a significance threshold of p < 0.001 instead of
0.01, which yielded 1,172 significant transcripts with 9%
expected false discovery rate (FDR). Specifying criteria for
selecting a statistically significant set of genes is a balance
between false negatives and false positives. Our approach was
to use the less stringent threshold of p < 0.01, yielding fewer
false negatives. As described below, we integrated our gene
sets with results from other mRNA profile datasets, which
could add more significance to a given gene that may have
only nominal significance in our initial dataset.
Gene expression signatures of estrogen regulation in vitro and in vivo Figure 1 (see following page)
Gene expression signatures of estrogen regulation in vitro and in vivo. (a) Expression data matrix of genes showing either induction or repression by E2 in 
vitro (p < 0.01 at 4, 8, 12, or 24 hour time points). Each row represents a gene; each column represents a sample. The level of expression of each gene in 
each sample is represented using a yellow-blue color scale (yellow, high expression); gray indicates missing data. Shown alongside our in vitro time course 
dataset are the expression values for the corresponding genes in two independent mRNA profile datasets of E2-treated breast cells ('Rae' dataset from [5] 
of cell lines MCF-7, BT-474, and T47-D; 'Finlin' dataset from [11] of MCF-7). (b) Alongside the in vitro datasets are the corresponding values for MCF-7 
xenografts with or without E2 supplementation (E2 withdrawn for 24 hours and 48 hours in the -E2 group). Genes in cluster 'B' (a) that show significant 
up-regulation by E2 in each of the four datasets are listed (an asterisk indicates positively correlated (p < 0.05) with age-correlation ERα expression (Figure 
2); bold type indicates having higher expression in ERα+ compared to ERα- breast tumors (p < 0.01) according to the 'van't Veer' dataset from [15]); italics 
indicates having higher expression in ERα- compared to ERα+ breast tumors). (c) Genes MYB (c-myb) and MYBL1 (A-MYB) are regulated by E2 in vivo. 
Expression patterns for genes from (b) were validated by RT-PCR. Shown are the mean and standard deviation of individual samples assayed in triplicate. 
Tumor volumes (expressed in mm3) are shown above each bar.http://genomebiology.com/2006/7/4/R28 Genome Biology 2006,     Volume 7, Issue 4, Article R28       Creighton et al. R28.3
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Figure 1 (see legend on previous page)
MCM4
ATAD2
BRIP1
HSPB8
FLJ22624
E2IG4
PAK1IP1
MRPS2
XBP1*
FLJ11184
FER1L3*
LOC56902
SIAH2*
IGF1R
ALG8
SGKL*
DNAJC10
FLJ22490
GREB1*
KIAA0830
TIPARP
MYBL1
PPAT
TPD52L1
CA12*
RARA
MYB*
TFF1*
NOL7
THRAP2
FHL2*
RASGRP1*
DLEU1
PTGES
CTNNAL1
WDHD1
FLJ10036
SLC25A15*
SLC39A8
TEX14
CISH*
ZNF259
THBS1
SLC9A3R1
PPIF
TIEG
NRIP1*
CTPS
TPBG
ADCY9
IRS1*
PLK4
EEF1E1
LRP8
WHSC1
CXCL12
ADSL
OLFM1
SDCCAG3
SNX24
IL17RB
FLJ10116*
FLJ10826
T47-D BT-474 MCF-7
time
Estrogen effects on
breast cancer cells
in vitro
expression index
low high
Rae dataset Finlin dataset
+E2
-E2 (24 hr)
-E2
+E2 (24 hr)
Estrogen effects on
xenograft tumors
in vivo
5
0
0
 
g
e
n
e
s
Cluster A
(385 genes)
Cluster B
(636 genes)
Cluster C
(302 genes)
Cluster D
(340 genes)
Cluster E
(363 genes)
Cluster F
(273 genes)
Cluster G
(146 genes)
Cluster H
(457 genes)
24 hr 12 8 4 0
-E2 (48 hr)
MYB (c-MYB)
0
2
4
6
8
10
12
Control E2 24 hrs post
E2 removal
48 hrs post
E2 removal
F
o
l
d
 
o
v
e
r
 
4
8
 
h
r
 
p
o
s
t
-
E
2
 
r
e
m
o
v
a
l
4
3
2
1
,
1
2
0
2
2
0
1
,
3
7
2
1
,
1
2
0
3
0
6
1
,
0
8
0
7
5
0
5
10
15
20
25
30
35
MYBL1 (A-MYB)
F
o
l
d
 
o
v
e
r
 
4
8
 
h
r
 
p
o
s
t
-
E
2
 
r
e
m
o
v
a
l
4
3
2
1
,
1
2
0
2
2
0
1
,
3
7
2
1
,
1
2
0
3
0
6
1
,
0
8
0
7
5
Control E2 24 hrs post
E2 removal
48 hrs post
E2 removal
(a) (b)
(c)
E
2
 
4
h
r
E
2
 
8
h
r
E
2
 
2
4
h
r
1
u
m
 
T
a
m
 
4
8
h
r
6
u
m
 
T
a
m
 
4
8
h
rR28.4 Genome Biology 2006,     Volume 7, Issue 4, Article R28       Creighton et al. http://genomebiology.com/2006/7/4/R28
Genome Biology 2006, 7:R28
We clustered the 3,501 putative E2 transcriptional targets
using a supervised method whereby each transcript was
assigned to one of the following expression patterns of inter-
est: transcripts induced or repressed early (within 4 hours)
but that return to baseline expression before 24 hours (Figure
1a, clusters A and E, respectively); transcripts induced or
repressed early (within 4 hours), but with sustained induction
or repression through 24 hours (clusters B and F); transcripts
induced or repressed through 24 hours beginning at interme-
diate time points (around 8 hours; clusters C and G); and
transcripts induced or repressed beginning at later time
points (12 to 24 hours; clusters D and H). Nearly all of the
transcripts could be assigned to one of these eight clusters
(four clusters for the up-regulated genes, four for the down-
regulated genes). One set of genes that did not fall into the
above clusters showed up- or down-regulation at only the 8
hour time point (Figure 1a), though these genes were rela-
tively few and no interesting patterns were found for them
with respect to other profile datasets examined (described
below). The clustering pattern was visualized as a color
matrix (Figure 1a), with genes in the rows and experiments in
the columns, and with yellow representing high expression
and blue representing low expression.
We examined each of the eight E2-regulated gene clusters for
significantly enriched (that is, over-represented) Gene Ontol-
ogy (GO) annotation terms [12] for clues as to the processes
that may underlie the coordinate expression of these genes. In
the cluster 'B' genes (Figure 1a), representing 636 unique
named genes (750 transcripts) induced early with sustained
induction by E2, significant GO terms (q-value < 0.02)
included terms related to ribosomal function and RNA and
protein processing, including 'ribosome biogenesis' (14 genes
found out of 34 represented in the entire set of profiled
genes), 'RNA metabolism' (28/212), and 'protein folding' (19/
145), as well as 133 genes with 'nucleic acid binding' function
(1,907 total). For the cluster 'E' genes (363 unique, 411 tran-
scripts; repressed at 4 hours but returning to baseline by 24
hours), significant GO terms included 'transcription factor
activity' (39/658), 'development' (60/1275), and 'cell adhe-
sion' (27/452). Cluster 'H' genes (repressed at 12 to 24 hours)
were enriched for genes located in the 'Golgi apparatus' (30/
274). No significant GO terms were found for cluster 'A' genes
(induced early but returning to baseline by 24 hours; 385
unique, 435 transcripts), cluster 'F' genes (repressed at 4
hours; 273 unique, 308 transcripts), or cluster 'G' genes
(repressed at 8 hours; 146 unique, 157 transcripts).
For the cluster 'C' genes (302 unique, or 346 transcripts) and
the cluster 'D' genes (340 unique, or 381 transcripts), which
showed sustained induction by E2 at 8 hours and 12 to 24
hours, respectively, significant GO terms found in both clus-
ters included terms related to cell division, including 'cell
cycle' (cluster C:53, cluster D:48, 593 total), 'cell prolifera-
tion' (C:59, D:65, 879 total), 'mitosis' (C:17, D:16, 98 total),
and 'DNA replication' (C:17, D:23, 154 total). An observed
enrichment of cell cycle-related genes within the C and D
clusters makes intuitive sense, as breast cancer cells stimu-
lated with estrogen will begin to divide and proliferate by 24
hours. Consistent with the GO term search results, when
referring to a dataset profiling gene expression during the cell
division cycle [13], we found an enrichment for genes showing
periodic expression during the cell cycle (618 genes total)
within the B, C, and D clusters, with the highest extent of
enrichment in C and D (B, 53 genes, p = 8E-06; D, 54, p = 3E-
17; E, 53, p = 3E-14).
Genes regulated by estrogen in breast cancer cell lines 
in vitro are also estrogen-regulated in xenograft tumors 
in vivo
We sought to determine whether the genes showing regula-
tion by estrogen in vitro could also be E2-regulated in vivo.
MCF-7 cells were grown as xenografts in ovariectomized ath-
ymic nude mice implanted with sustained-release E2 pellets.
After measurable tumors were established (approximately 4
weeks), the mice were randomized into control (continued E2
supplementation, four mice) or E2 withdrawal (surgical
removal of pellet, four mice) groups; tumors 24 hours and 48
hours later were collected and profiled for global mRNA
expression using Affymetrix arrays (eight profiles in all).
We compared the mRNA profile data from the tumor
xenografts (with and without E2) side-by-side with our data
for E2-regulated genes in vitro. We observed many of the
same genes appearing regulated by E2 in vivo in the same
direction as what we observed in vitro (Figure 1b), thereby
demonstrating how these two very different experimental
models can yield similar results. Of the 435 cluster A tran-
scripts derived from the in vitro data (Figure 1a), 22% showed
up-regulation by E2 in tumor xenografts; of the 750 cluster B
transcripts, 45%; of the 346 cluster C transcripts, 48%; and of
the 381 cluster D transcripts, 27%. Similarly, while only 4% of
the 411 cluster E transcripts showed down-regulation by E2 in
vitro, the percentage for the 308 cluster F transcripts was
32%; for the 157 cluster G transcripts, 50%; and for the 499
cluster H transcripts, 42%. We validated our xenograft micro-
array results using real-time PCR analysis for genes MYB (v-
myb myeloblastosis viral oncogene homolog (avian), or c-
myb) and MYBL1 (v-myb homolog-like 1, or A-MYB) (Figure
1c). GREB1, another gene arising from our analysis, had been
previously validated by our group as being induced by E2 in
vivo [5].
We compared our xenograft and in vitro mRNA profile data
with two other independent in vitro profile datasets from pre-
vious studies: one dataset generated by our group [5] of three
ERα-positive cell lines (MCF-7, T47D, and BT-474) grown in
steroid-depleted medium or in the presence of E2 for 24
hours (the 'Rae' dataset); and another dataset from a similar
experiment carried out by a different group using a different
microarray platform (cDNA) [7] and MCF-7 cells treated with
E2 or ICI 182,780 (the 'Finlin' dataset). When viewing thehttp://genomebiology.com/2006/7/4/R28 Genome Biology 2006,     Volume 7, Issue 4, Article R28       Creighton et al. R28.5
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qualitative results of our original in vitro dataset side-by-side
with those of the other three datasets, we found that most of
the genes in our E2-regulated gene sets showed E2-regulation
in the same direction in at least one other dataset (Figure 1a),
thereby adding confidence to these genes as being bona fide
E2 targets. Of the 750 cluster B transcripts from the original
dataset, 73 (63 unique genes) showed E2 induction in each of
the other three datasets (xenograft dataset, p < 0.05; Rae
dataset, p < 0.05; Finlin dataset, average fold change >1.4).
Many of the cluster B transcripts were significant in one or
two of the other three datasets. In particular, we identified
172 cluster B transcripts (148 unique genes) that were signif-
icant in the xenograft and Rae datasets but not in the Finlin
dataset, 47 of these transcripts not being represented in the
Finlin dataset. Of the 750 cluster B transcripts, 215, or 29%,
did not show significant regulation in any of the other three
datasets. We had anticipated a 25% FDR for our initial gene
selection (see above), and so we might expect this set of 215
transcripts to be highly enriched for transcripts giving spuri-
ous results due to multiple gene testing.
Some genes appeared regulated by E2 in vitro but not in vivo;
162 of the cluster B transcripts (142 unique genes) also
showed significance in the Rae dataset but not in the
xenograft dataset. Similarly, our data might reveal genes that
appear regulated by estrogen in vivo but not in vitro. Of the
459 most significantly E2-induced transcripts in the in vivo
dataset (p < 0.05, fold change >1.5), 97 did not show any sim-
ilar trend towards significance in either of the in vitro
Affymetrix datasets (p > 0.20). Possible reasons for this dis-
parity have been mentioned above; however, these putative in
vivo-specific targets of E2 may be enriched for false positives,
and so genes of interest in this set would need to be independ-
ently validated.
In our analyses below involving human tumor profile data, we
focused on our sets of in vitro E2-regulated genes, as we
wanted to determine whether genes regulated at different
time points might show differences with respect to patterns in
human tumors. However, we did find the set of genes induced
by E2 in vivo to generally show the same patterns (results not
shown) described below for cluster B (the cluster of early and
sustainable induced genes).
A significant number of genes induced by estrogen in 
vitro are correlated with age-corrected ERα mRNA 
expression in ERα+ human breast tumors in vivo
We next examined the mRNA expression patterns of our in
vitro E2-regulated gene sets in human breast tumors to deter-
mine how these genes might be pathologically relevant (that
is, relevant from a disease standpoint). We hypothesize that
ERα+ breast cancers would express a significant number of
the E2-regulated genes observed in our in vitro data set. Since
pathologically classified ERα+ breast cancers have been
shown to express varying levels of ERα both at the protein
and mRNA level, we examined the dataset from van de Vijver
et al. [14] of 295 patient breast tumor mRNA expression pro-
files, focusing first on the subset of 226 ERα+ tumor profiles
to determine whether E2-regulated genes might be correlated
with ERα expression in these tumors. ERα mRNA level had
been measured by a 60-mer oligonucleotide on the microar-
ray, which was observed to correlate highly with the meas-
ured protein level [15].
Using the breast tumor profile dataset, we constructed a list
of the profiled genes ordered according to similarity with ERα
mRNA expression (that is, genes having high expression
when ERα has high expression and having low expression
when ERα has low expression would be at the top of this list).
We next used Gene Set Enrichment Analysis (GSEA) [16,17]
to capture the position of genes in the E2-induced cluster B
genes (induced within 4 hours, Figure 1a) within this ordered
list. GSEA determines whether a rank-ordered list of genes
for a particular comparison of interest (for example, correla-
tion with ERα in human breast tumors) is enriched in genes
derived from an independently generated gene set (for exam-
ple, the cluster B genes). In fact, we did not see a significant
enrichment of cluster B genes within the top tumor ERα cor-
relates, though a trend towards significance was evident (p =
0.12, Figure 2b). This result caused us to consider other fac-
tors in addition to ERα expression to assess the amount of
estrogen signaling in tumors.
Along with ERα status, age is thought to have an important
impact on survival in breast cancer, with younger patients
having a poorer outcome [18]. We might expect a trend of
tumors from younger patients having more estrogen signal-
ing, as younger patients have higher levels of estrogen. In fact,
when ranking the genes in the breast tumor dataset by inverse
correlation with age at diagnosis (genes at the top of the
ranked list would be most highly expressed in younger
patients compared to older patients), we did see an enrich-
ment of the E2-induced cluster B genes within genes more
highly expressed in young patients (GSEA nominal p = 0.015,
FWER (Family-Wise Error Rate) p = 0.055). Besides cluster
B, none of the in vitro E2-regulated gene clusters showed
similar coordinate expression in either younger or older
patients (Figure 2d).
Gene expression data may be combined with other clinical
variables to reveal patterns that might not have been
observed when considering the variables in isolation. In the
study by Dai et al. [18], one group used ERα level and its var-
iation with age to subdivide the patients represented in the
tumor profile dataset used in this study. When the ERα level
obtained from the microarray measurements was plotted ver-
sus age for the ERα+ patients, the patients appeared distrib-
uted into two distinct subpopulations (Figure 2a). The
profiles were stratified into an 'ER/age high' group (meaning
high ERα expression for their age), and an 'ER/age low'
group, with patients in the 'ER/age high' group having poor
overall outcome. Based on these previous findings, weR28.6 Genome Biology 2006,     Volume 7, Issue 4, Article R28       Creighton et al. http://genomebiology.com/2006/7/4/R28
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A significant number of genes induced by E2 in vitro are correlated with age-corrected mRNA expression of ERα in human breast tumors Figure 2
A significant number of genes induced by E2 in vitro are correlated with age-corrected mRNA expression of ERα in human breast tumors. (a) Scatter plot 
of ERα expression versus age in ERα+ breast tumor samples from the profile data from [14]. The dotted line is used to stratify the samples into ER/age 
high (above the line) and ER/age low (below the line) groups. Figure adapted from [18]. (b) GSEA of the cluster B genes (induced early by E2 and sustained 
over time; Figure 1a) against the overall ranking of genes according to similarity with ERα mRNA (ESR1) expression in the cohort of ERα+ breast tumor 
profiles from [14]. The ES statistic (the maximum of the ES running sum) is high if many genes in the set of interest appear near the top of the ranked list. 
Vertical bars along the ES plot denote occurrences of a cluster B gene. (c) GSEA of the cluster B genes against gene ranking by similarity with ESR1 
expression as corrected for patient age (using dotted line in (a)). (d) GSEA results for estrogen-regulated gene clusters A to H against four different gene 
rankings tested. The FWER p-value corrects for multiple gene set testing. (e) Enrichment of cluster B genes within the set of genes showing positive 
correlation (p < 0.05) with ESR1 expression in a set of tumor profiles from patients within a narrow age range of 41 to 44 years. In the gene list: an asterisk 
indicates negatively correlated (p < 0.05) with age in ERα+ tumors; bold type indicates having higher expression in ERα+ compared to ERα- breast tumors 
(p < 0.01); and italics indicate induced by E2 in breast tumor xenografts (p < 0.05; Figure 1b).
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AND
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PGR correlation in ER+ tumors
ES nominal P FWER P
0.015 0.072 0.351
0.190 0.001 0.004
0.091 0.316 0.965
0.012 0.781 1.000
0.011 0.826 1.000
0.022 0.801 1.000
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hypothesized that patients in the 'ER/age high' group would
have higher expression of E2-induced genes. We developed
an 'age-corrected' measure of ERα expression by using the
dividing line (as defined by Dai et al.) between the 'ER/age
high' and 'ER/age low' groups (Figure 2a), rather than the
zero point, as the baseline. When ranking the genes in the
tumor dataset by correlation with this age-corrected ERα, we
found a significant enrichment for E2-induced cluster B
genes (GSEA nominal p = 0.001, FWER p = 0.004; Figure 2c)
where we had not found such an enrichment when consider-
ing ERα independently of age (Figure 2b).
Another way to correct for patient age when relating tumor
ERα levels to coordinate expression of E2-inducible genes is
to consider a set of tumors for which patients were roughly
the same age. From the 226 ERα+ tumor profiles, we consid-
ered a subset of 61 profiles from patients with ages 41 to 44.
Patients from this age group were evenly divided between the
'ER/age high' and 'ER/age low' (Figure 2a). When ranking the
genes in the tumor dataset by correlation with ERα in these
patients (without correction for age), we did see an enrich-
ment of cluster B genes within the top ERα correlates by
GSEA (nominal p = 0.033). Out of the top 720 genes posi-
tively correlated with ERα expression (p < 0.05), 68 were rep-
resented in cluster B (Figure 2e; p  < 10E-60, one-sided
Fisher's exact).
A significant number of genes induced by estrogen in 
vitro are correlated with PR mRNA expression in ERα+ 
human breast tumors in vivo
An additional indicator of estrogen signaling activity in breast
tumors is the higher expression of known estrogen-inducible
targets, such as progesterone receptor (PR). The PGR gene
encoding PR was among our cluster B genes. PR expression is
used clinically in addition to ERα as an important molecular
prognostic factor for response to antiestrogen therapy in
breast cancer patients, as it indicates the endpoint of estrogen
action [19]. In the ERα+ breast tumor profile dataset from
van de Vijver et al. [14], PGR was correlated with both ERα
(Pearson's correlation p < 0.01) and age-corrected ERα (p =
0.05), and over half of the 674 genes most correlated (p <
0.05) with PGR overlapped with the set of 1,338 genes most
correlated (p < 0.05) with age-corrected ERα (enrichment p
~ 0). As we anticipated, GSEA showed an enrichment in the
E2-inducible genes are enriched in ER+/PR+ breast tumors compared to ER+/PR- breast tumors Figure 3
E2-inducible genes are enriched in ER+/PR+ breast tumors compared to ER+/PR- breast tumors. Expression patterns for the cluster B genes (induced by 
E2 in vitro within 4 hours; Figure 1a) are shown alongside the corresponding patterns in MCF-7 xenografts (Figure 1b) and in two independent breast 
tumor datasets from van de Vijver et al. [14] and Wang et al. [20]. Genes showing significant correlation with PGR in both van de Vijver and Wang datasets 
(p < 0.05 in each) are highlighted and listed: italics indicate more highly expressed in ER+ compared to ER- tumors (p < 0.01); bold type indicates 
significantly correlated with age-corrected ER expression (p < 0.05; see Figure 2). Enrichment p value by one-sided Fisher's exact test.
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top PGR gene correlates for cluster B genes (nominal p =
0.001, FWER p = 0.004; Figure 2d). We examined a second
ERα+ tumor profile dataset from Wang et al. [20] and identi-
fied 50 genes from cluster B that were significantly correlated
with PGR (p < 0.05) in both the van de Vijver and Wang data-
sets (Figure 3), where about half the number of genes would
have been expected by chance (p < 0.0001, Fisher's exact).
No significant enrichment of E2-regulated genes in vitro 
within genes associated with ERα+ breast tumor status
We next considered ERα-negative tumors along with ERα-
positive tumors. One might expect ERα+ tumors to express
E2-induced genes more highly compared to ERα- tumors.
From the 295 cohort of breast tumor profiles, we selected 79
for which ERα was measured at the protein level, with ERα
levels in the ERα+ tumors from 80% to 100% of cells [15].
Surprisingly, when ranking genes in the tumor profile dataset
by higher expression in the ERα+ compared to the ERα-
tumors, we did not observe any evidence for enrichment of
E2-induced genes within the top ERα+ genes (GSEA p  =
0.405 for cluster B genes; Figure 2d). Out of the top 1,965
expressed genes in ERα+ tumors (p < 0.01), 110 were repre-
sented in cluster B, which did not represent a significant over-
lap (p = 0.11). We also tried considering a subset of the ERα+
tumors that had the highest PR levels, but could still find no
statistical enrichment of E2-regulated genes in the genes dis-
tinguishing this ERα+ subset from the ERα- tumors (results
not shown). On the other hand, contrary to our initial
expectations, we did see an enrichment of E2-induced genes
within the top ERα- genes. Out of the top 1,904 expressed
genes in ERα- tumors (p < 0.01), 132 were represented in
cluster B (enrichment p = 3.7E-05). If, however, we consider
the set of genes that are both induced by E2 in our models and
correlated with age-corrected ERα in ERα+ breast tumors,
we do find this set to be highly enriched for genes more highly
expressed in ERα+ compared to ERα- tumors (Figure 2e).
Genes induced by estrogen in vitro are enriched for 
transcriptional targets of Myc
We may expect that many of the genes in our E2-regulated
gene clusters are not direct transcriptional targets of E2, but
rather secondary targets through one or more intermediates.
Within the cluster B genes (Figure 1a), with sustained induc-
tion by E2 at early time points, about 20% of the 639 genes
had the GO annotation of 'nucleic acid binding,' suggesting
that many of the genes regulated by E2 encode for transcrip-
tion factors that may themselves go on to regulate additional
genes. One transcription in cluster B is the c-Myc oncogene
(myc), which is a well-known direct target of estrogen.
Knockdown of myc expression inhibits estrogen-stimulated
breast cancer cell proliferation [21]. It is, therefore, conceiva-
ble that a number of genes in our E2-regulated gene clusters
would be direct targets of myc as well as secondary targets of
E2. We referred to two public datasets of putative myc target
genes (Figure 4a): one mRNA profile dataset of changes
caused by activation of myc in primary human fibroblasts
[22] (252 up-regulated, 238 down-regulated by myc with p <
0.01), and another dataset of 960 genes with predicted myc
binding sites in their promoter regions [23]. Both the cluster
B and cluster C genes (induced by E2 by 4 hours or 8 hours,
respectively) showed high enrichment for both myc-induced
mRNAs (B, 27 genes, p = 1.6E-04; C, 20, p = 2.3E-06) and
genes with predicted myc binding sites (B, 94, p = 1.3E-10; C,
44, p = 1.6E-05). No enrichment was observed for mRNAs
down-regulated by myc within mRNAs repressed by E2.
We examined the expression patterns of the E2-regulated
gene clusters with respect to myc in human tumors. We had
found that many of the E2-induced genes were correlated
with (age-corrected) ERα mRNA expression in tumors (see
above), and so we reasoned that other genes within the estro-
gen mRNA signature that were specifically involved in the
myc pathway would be correlated with myc in tumors. We
examined four mRNA profile datasets of human tumors: the
dataset of ERα+ breast tumor profiles used above (Figure 2);
a dataset of 69 ERα- breast tumors [14]; a compendium of 174
tumors from 11 different histological types (including breast;
the 'Novartis' dataset) [24]; and a second compendium of 138
tumors from 13 different types (the 'MIT' dataset) [25]. In all
four datasets, GSEA showed very high enrichment for both
cluster B and cluster C E2-induced genes in vitro within the
top myc correlates in vivo (Figures 3d and 4d). The in vitro
set of myc targets from [22] (p < 0.01) were also significantly
correlated with myc expression in each of the tumor datasets.
In the tumor datasets, myc expression was not significantly
correlated with ERα mRNA, and the E2-induced genes most
correlated with ERα mRNA expression in ERα+ breast
tumors were distinct from the E2-induced genes most corre-
lated with myc expression (Figures 2e and 3b).
We also considered an mRNA profile dataset measuring the
response to serum exposure in human fibroblasts. Gene
expression profiles taken from fibroblast cultures derived
from 10 anatomic sites were cultured asynchronously in 10%
fetal bovine serum (FBS) or in media containing only 0.1%
FBS [26]. Many similarities would be expected between the
gene expression patterns in fibroblasts in high serum relative
to low serum conditions and the expression patterns in ERα+
breast cells in estrogen-rich relative to estrogen-deprived
conditions. We observed that fibroblasts in high serum over-
expressed myc mRNA (p = 0.00015), and so we might expect
that many of the genes up-regulated in fibroblasts in response
to serum would be myc targets or closely related to the myc
pathway. Out of the (unique) 908 E2-induced genes in clus-
ters B and C (Figure 1a), 425 were also significantly up-regu-
lated (p < 0.05) in fibroblasts in high serum. Within the E2-
induced gene signature, the fibroblast serum-induced genes
overlapped with the myc  target genes (Figure 4b). Con-
v e r s e l y ,  w e  i d e n t i f i e d  3 0 8  g e n e s  i n  c l u s t e r s  B  a n d  C  t h a t
showed no significant serum induction in fibroblasts (p  >
0.20); these genes may be more unique to the estrogen sign-http://genomebiology.com/2006/7/4/R28 Genome Biology 2006,     Volume 7, Issue 4, Article R28       Creighton et al. R28.9
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aling pathway rather than general to processes of growth and
proliferation.
One possibility to consider is that the associations found here
between the estrogen pathway and the myc  pathway are
related to processes of cell division and would be evident in
any scenario of highly proliferating cells. However, when
examining two public mRNA profile datasets of LNCaP pros-
tate cancer cells stimulated to profilerate with androgen
treatment [27,28], myc  was not found to be up-regulated
(Chen dataset p = 0.53), and there was no enrichment for myc
targets within genes inducted by R1881 in LNCaP (Chen data-
set enrichment p = 0.10). We examined the expression pat-
terns of cell cycle genes from [13] with respect to myc
expression in tumors; in three of four tumor datasets we did
see an enrichment of cell cycle genes within the top myc cor-
relates (Figure 4d), though only a few of these were found in
the overlap between E2-induced genes and myc target genes.
Genes induced by E2 in vitro are enriched for transcriptional targets of Myc Figure 4
Genes induced by E2 in vitro are enriched for transcriptional targets of Myc. A conditional Myc-estrogen receptor (Myc-ER) fusion protein was used to 
induce Myc transcriptional activity. Conditional activation of Myc occurs upon stimulation with the anti-estrogen 4-hydroxytamoxifen (OHT). Gene 
expression profiles were taken of primary human fibroblasts with Myc-ER to identify transcriptional targets of Myc [22] (CHX, cycloheximide). (a) 
Enrichment of Myc targets (p < 0.01) within each of the distinct clusters of estrogen-regulated genes (Figure 1). Values indicating significance of overlap (p 
< 0.05) between two given genes sets are in bold. (b) Expression data matrix for cluster B and C genes that were also represented in the Myc-ER dataset, 
alongside the corresponding values in both the Myc-ER dataset and in a profile dataset from [26] of human fibroblasts grown in high and low serum 
conditions, in which Myc is up-regulated in the high serum group. Myc targets (p < 0.01) are listed (asterisk indicates has predicted Myc TF site in 
promoter region; italics indicate cell cycle gene from [13]). (c) GSEA of the cluster B genes against the overall ranking of genes according to similarity with 
myc mRNA expression in a compendium of tumor profiles from breast and 10 other tissues types from [24]. (d) GSEA results for estrogen-regulated gene 
clusters A to H, genes induced by Myc-ER+OHT in fibroblasts (p < 0.01), and cell cycle genes [13], against gene rankings by Myc correlation in four 
different datasets (clusters A to H, FWER p, Myc and cell cycle, nominal p).
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Discussion
Numerous studies have sought to characterize the transcrip-
tional network associated with the estrogen response using
cell culture experiments. However, when relying exclusively
on results from in vitro studies, concerns may arise that many
of the effects observed may be artifacts of the cell line model.
Data from in vitro models represents dynamic information,
where cells can be readily manipulated and the effects
observed. Cells can be manipulated to a certain extent in vivo,
for instance using the tumor xenograft model, though with
considerably greater effort. An abundance of gene expression
data from human tumors is available to the public domain.
However, this type of in vivo data represents more static
information, where the associations observed may be patho-
logically relevant, but where cause-and-effect associations
cannot be distinguished from mere correlation. An emerging
area of DNA microarray analysis of cancer is that of relating
profile data from in vitro bench experiments to profile data
from in vivo experimental models and from human tumors.
Recent attempts at correlating gene profiles observed in cell
line studies, in which oncogenes such as cyclin D1 or k-ras
were manipulated, with profiles obtained from patient
tumors of various types, have found significant similarities
between the in vitro and in vivo systems [16,17]. These simi-
larities may be subtle in some cases but can be observed using
more advanced analytical techniques such as GSEA.
Using global mRNA expression profiling, we have identified
transcription networks of hundreds of genes that are either
stimulated or inhibited by E2 in vitro. However, cultured cells
in an in vitro environment may differ considerably in behav-
ior compared to those of the same cancer cells that proliferate
and form tumors in vivo [29]. To determine the physiological
relevance of these genes, we compared them with genes
showing E2-regulation in vivo in xenograft tumors, observing
a highly significant number of the same genes being regulated
by E2 in vivo as well as in vitro. Our findings of good agree-
ment between the in vivo and in vitro estrogen-regulated pro-
grams differ from the conclusions reached by one recent
study by Harvell et al. [30], in which mRNA profiles were
taken of ERα+ T47-D-Y human breast cells grown as
xenografts in nude mice under the following conditions: E2
supplementation for 8 weeks, no E2 for 8 weeks, and E2 for 7
weeks followed by E2 withdrawal for one week. The Harvell
study found little overlap between E2-regulated genes in vivo
versus in vitro. One way to perhaps explain this disparity is
the differences in xenograft models and experimental design
between the two studies. We suspect that the Harvell study
may have selected for genes involved with the adaptation of
breast cells to long term estrogen withdrawal, whereas our
model focuses on short-term changes in estrogen signaling.
We found little overlap between in vivo E2-regulated genes in
our study and the Harvell study. Out of 1,073 genes induced
in vivo in our data (p < 0.01), only 15 were in the top set of 188
reported by Harvell (9 class I and 6 class II genes, as
described in [30]). Furthermore, genes such as GREB1, which
was previously confirmed by our group by real-timePCR as
E2-regulated in vivo [5], did not appear to be significant in
the Harvell data. These discrepancies may be due to differ-
ences in the sensitivity and specificity of the separate DNA
microarray platforms used.
We might expect the cluster A and E genes from our in vitro
data (Figure 1a) to have less agreement with the xenograft
data compared to the other clusters, as the A and E genes did
not show sustained E2 regulation at 24 hours. Other dispari-
ties between our xenograft and in vitro data might similarly
be attributed to differences in the two experimental models.
Since estrogen must be provided for tumor formation, estro-
gen was withdrawn for 24 and 48 hours in order to generate
the non-estrogen stimulated tumor sample. Thus the dynam-
ics of the drop in estrogen concentration over time, the half
life of the estrogen induced mRNAs and the changes in gene
expression associated with the loss of the proliferative drive
will all have contributed to the disparity seen. The expression
pattern in the xenograft model is also complicated by the
effects of estrogen induced paracrine factors acting on the
tumor cells. Currently, we are carrying out experiments to see
whether the genes regulated by E2 in vivo in both T47D and
BT-474 are similar to those showing E2 regulation in MCF-7
xenografts. Based on the above results, we would expect this
to be the case, as the in vitro E2-stimulated profiles show a
remarkable amount of similarity among the three different
cell lines.
To determine the clinical relevance of genes regulated by E2
in our experimental models, we compared them with genes
correlated with PR expression in human ERα+ breast tumors,
with genes correlated with ERα expression, with genes corre-
lated with patient age, and with genes correlated with ERα
expression corrected for patient age (which overlap highly
with the gene most correlated with PR expression). We dem-
onstrate how early inducible genes of estrogen as a group are
expressed together in ERα+ breast tumor with relatively high
levels of PR and of ERα for the patient's age, as well as in
ERα+ tumors from younger patients compared to older
patients. These findings indicate that ERα+ breast cancers
with higher levels of estrogen signaling, either through
increased ERα expression or the increased estrogen produc-
tion expected in younger patients, express genes observed to
be induced by estrogen in vitro. We feel that our results pro-
vide significant validation of a widely used in vitro model of
estrogen signaling as being pathologically relevant to breast
cancers in vivo. Furthermore, our analysis demonstrates how
molecular data can be combined with clinical data such as
patient age to uncover associations that may not have been
evident when considering either clinical or molecular data
alone.
While we observed coordinate expression of E2-regulated
genes in ERα+ breast tumors, we did not observe enrichment
for E2-induced genes in ERα+ breast tumors compared tohttp://genomebiology.com/2006/7/4/R28 Genome Biology 2006,     Volume 7, Issue 4, Article R28       Creighton et al. R28.11
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ERα- tumors as we might have expected. These observations
are consistent with those of previous microarray analyses
[10,31], indicating that there may be more to the molecular
differences between ERα+ and ERα- tumors than simply a
loss of estrogen signaling in the ERα- tumors. This disparity
may be accounted for in part by the fact that ERα- tumors are
more aggressive and express cell proliferation genes more
than ERα-positive tumors [15,32], and, therefore, similarities
between cells proliferating in response to E2 in vitro and cells
within tumors with a high proliferative  index would be
expected.
We also observed that E2-inducible myc expression plays an
important role in the estrogen transcription network. Genes
induced by E2 were enriched for transcriptional targets of
myc. The public Oncomine database of cancer gene expres-
sion [33,34] showed Myc to be over-expressed in ERα-
tumors compared to ERα+ tumors in multiple breast tumor
datasets. We find in this study that genes involved in the myc
network were coordinately expressed with Myc in both ERα-
and ERα+ tumors. This observation indicates that the myc
pathway, which is essential for E2-mediated growth, remains
active in the ERα- tumors, and is not shut down along with
other components of the estrogen pathway with the loss of
ERα expression. The presence of a gene expression signature
for myc activation within the E2-induction signature may fur-
ther explain in part the discordance we observed between the
E2 signature and the gene expression differences between
ERα+ and ERα- breast tumors, as the myc portion of the E2
signature is enriched in the ERα- rather than the ERα+
tumors. However, when we removed candidate myc targets
from the E2 signature, we still did not observe enrichment of
the remaining E2-inducible genes within the ERα+ tumors
(results not shown). As more experimental in vitro signatures
become available (for example, signatures of activation for
genes other than myc), it may be possible to further dissect
the E2 signature into meaningful subgroups.
In future studies, we plan to examine the functional roles of
specific genes arising from our E2-regulated gene signatures,
as well as their relevance to such clinical variables as patient
response to therapy. By combining in vitro gene expression
data on E2 stimulation with our xenograft data, as well as
with data from human tumors, we can better select for genes
having critical roles in the estrogen response in breast cancer,
such as GREB1, which has recently been shown by our group
to be a critical regulator of hormone dependent breast cancer
[5]. We also plan to further explore the gene expression dif-
ferences between ERα+ and ERα- tumors, and whether genes
other than the ER gene might be involved in the ERα-
phenotype.
Materials and methods
Cell lines, culture conditions and growth assays
Tumor cell lines were maintaine d  a n d  g r o w t h  a s s a y s  p e r -
formed as described previously [5]. For defined estrogen cul-
ture experiments, cells were washed and grown in steroid
depleted media (phenol red-free IMEM (Improved Minimal
Essential Media) supplemented with 10% charcoal stripped
calf bovine serum; Valley Biomedical Products, Winchester,
VA, USA) as described previously [5].
MCF-7 xenograft model
MCF-7 cells (about 107) were inoculated subcutaneously in
the mammary fat pad region of 6-week old ovariectomized
athymic nude mice containing sustained-released E2 pellets
(0.72 mg/pellet, 60-day relea s e ;  I n n o v a t i v e  R e s e a r c h  o f
America, Sarasota, FL, USA) as described previously [5].
After 4 weeks, the mice were randomized into control (contin-
ued E2 supplementation) or E2 withdrawal (surgical removal
of pellet). Tumors were excised 24 and 48 h later, RNA
extracted and global gene expression patterns were obtained
using the Affymetrix GeneChip as described below. All animal
experiments were performed according to a protocol
approved by the University of Michigan Guideline for Use and
Care of Animals in compliance with US and UKCCCR (Unite
Kingdom Coordinating Committee on Cancer Research)
guidelines [35].
RNA extraction
Total RNA was isolated using TRIzol Reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacture's instruc-
tions. Yield and quality were determined by spectrophotome-
try (Beckman DU 640, Beckman Coulter, Inc., Fullerton, CA,
USA) and using a Bioanalyzer RNA 6000 Nano chip (Agilent
Technologies, Palo Alto, CA, USA). All samples were stored at
-80°C. RNA for microarray analysis was labeled and hybrid-
ized according to the Affymetrix protocol (Affymetrix Gene-
Chip Expression Analysis Technical Manual, Rev. 3) by the
University of Michigan Comprehensive Cancer Center
Affymetrix and cDNA Microarray Core Facility.
Affymetrix microarray analysis
Gene expression patterns were determined using Affymetrix
Genechip Arrays. Arrays were normalized and compared
using DNA-Chip Analyzer software (dChip) [36]. Array data
has been deposited in the public Gene Expression Omnibus
(GEO) database, accession GSE3834. The MCF-7 in vitro
profiles were generated using the Affymetrix U133A platform,
while the other profiles were generated on the U133 Plus 2.0
platform; we therefore considered only the 22,283 probe sets
shared between the two platforms in our analysis. Gene
expression values were log-transformed. Expression values
within each cell line were first transformed to standard devi-
ations from the mean. Two-sample t tests were performed as
criteria for determining significant differences in mean gene
mRNA levels between groups of samples. Expression values
were visualized as color maps using the Cluster and JavaR28.12 Genome Biology 2006,     Volume 7, Issue 4, Article R28       Creighton et al. http://genomebiology.com/2006/7/4/R28
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TreeView software [37]. GO annotation terms were obtained
and searched for enrichment within gene sets as described in
[29], with GO terms applying to 10 or more genes being con-
sidered for enrichment, and with a 'q-value,' using the
method in [38], indicating significance after correcting for
multiple term testing. Significance of overlap between two
independently derived gene sets (for example, a given estro-
gen-regulated gene cluster and Myc target genes) was deter-
mined by one-sided Fisher's exact test.
When mapping genes across our estrogen mRNA profiling
datasets (time course, xenograft, and datasets from [5]), the
Affymetrix probe Id (corresponding to a specific mRNA tran-
script) was used. When mapping genes from our estrogen
datasets to independent datasets from other laboratories and
other platforms, the gene symbol was used; where a gene was
represented multiple times on a given platform, the gene with
the most significant patterns of interest was used (for exam-
ple, most correlated with ERα expression in either direction
for the dataset from [14]). For the Myc profiling dataset from
[22], values within each of the three experiments were first
transformed to standard deviations from the mean, and a t
test determined significance between a conditional Myc-ER
fusion protein activated by 4-hydroxytamoxifen (Myc-
ER+OHT) and control+OHT groups. The xenograft profiling
experiments were carried out on two separate dates (two pro-
files +E2, two profiles -E2 on each occasion), and so expres-
sion values within each batch of profiles were first
transformed to standard deviations from the mean before
comparing the +E2 and -E2 groups.
GSEA was carried out essentially as described in [16], with the
exception that our tests were one-sided (as in [17]). Briefly,
the common population of genes represented in the given in
vivo  tumor profile dataset and our E2 Affymetrix dataset
were ranked based on a particular metric applied to the
expression values in the tumor dataset (for example, correla-
tion with ERα expression). The significance of the positions of
a given gene set of interest (for example, estrogen-regulated
gene cluster) being located near the top of the ranked list was
assessed by the Kolmogorov-Smirnov score, from which an
'ES' statistic was derived. If a gene was represented more than
once on a given platform, then the highest ranking for the
gene was used for the GSEA. The significance of the ES statis-
tic was determined by carrying out the same analysis using
1,000 random permutations of the sample labels in the tumor
dataset.
Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a table providing
a complete list of genes regulated by E2 in vitro in each of the
eight gene clusters shown in Figure 1.
Additional File 1 Complete list of genes regulated by E2 in vitro in each of the eight  gene clusters shown in Figure 1 Complete list of genes regulated by E2 in vitro in each of the eight  gene clusters shown in Figure 1. Click here for file
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